Curriculum Vitaes
Profile Information
- Affiliation
- Professor, Faculty of Medical Sciences, Fujita Health University理事長, 医薬品適正使用推進機構, NPO
- Degree
- Ph.D.
- J-GLOBAL ID
- 201101030936121945
- researchmap Member ID
- B000004803
- External link
藤田医科大学大学院医療科学研究科 客員教授
学歴
1968年3月岐阜薬科大学製薬学科卒業
1973年3月大阪大学大学院薬学研究科博士課程単位取得後中退
1977年12月東北大学にて博士号修得(薬学)
職歴
1973年 4月名城大学薬学部 助手
1978年10月~1981年5月米国ミシシッピー州立大学メディカルセンター 客員助教授
1982年 4月名城大学薬学部 講師
1984年 4月名城大学薬学部 助教授
1990年 1月名古屋大学大学院医学系研究科臨床情報学講座医療薬学分野・医学部附属病院薬剤部 教授・部長(併任)
2006年 1月特定非営利活動法人医薬品適正使用推進機構理事長
2007年 3月名古屋大学を定年退職
2007年 4月より名城大学大学院薬学研究科 薬品作用学研究室 教授
2012年 3月名城大学を定年退職
2012年 4月より名城大学薬学部寄附講座 地域医療薬局学講座特任教授
2015年 3月より名城大学薬学部 特任教授
2015年12月より藤田医科大学大学院保健学研究科(現 医療科学研究科) 客員教授
現在の主な研究分野:神経精神薬理学:精神疾患動物モデルの作成と新薬開発への応用、薬物依存、医薬品の適正使用についての研究
Research Interests
31Research Areas
5Research History
10-
Apr, 2015 - Mar, 2016
-
Apr, 2011 - Mar, 2015
-
2007 - 2011
-
1990 - 2007
Education
3Committee Memberships
4-
2004 - Present
-
2001 - Present
-
1992 - Present
-
2008 - 2010
Awards
9-
2008
-
2007
-
2001
Papers
794-
Behavioural Brain Research, 496 115832-115832, Jan, 2026
-
British Journal of Pharmacology, Dec 21, 2025Abstract Background and Purpose Lifestyle is closely related to major depressive disorder (MDD). Given the growing focus on the impact of diet on mental health, this study examined how dietary habits affect the pathophysiology of MDD. Experimental Approach Health check‐up data were analysed. Mice received sucrose under chronic unpredictable mild stress (CUMS) and were evaluated by behavioural, neurochemical and metabolic analysis. Key Results Health check‐up data showed increased sucrose intake in MDD patients. When mice received sucrose under CUMS, hyperactivity and aggression were attenuated, although social deficits or behavioural despair induced by CUMS persisted, and recognition memory was impaired. The behavioural changes were associated with dysfunction of the locus coeruleus‐prefrontal cortex circuit, caused by impaired noradrenaline release due to presynaptic α 2 ‐adrenoceptor upregulation, and postsynaptic α 1 ‐adrenoceptor and β 1 ‐adrenoceptor downregulation. α 2 ‐Adrenoceptor antagonism by atipamezole rescued behavioural changes induced by sucrose intake under CUMS, whereas α 2 ‐adrenoceptor agonism by guanfacine in CUMS mice mimicked these behavioural changes. Among the antidepressants, mirtazapine effectively increased noradrenaline release and rescued behavioural changes induced by sucrose intake under CUMS. Sucrose intake under CUMS induced peripheral hyperglycaemia and dysregulation of central glucose metabolism. Glucose transporter inhibition by phloretin rescued behavioural changes induced by sucrose intake under CUMS. Intracerebroventricular and systemic streptozotocin administration reproduced these behavioural changes and α 2 ‐adrenoceptor upregulation. Conclusions and Implications Our findings suggest that the observed behavioural changes are associated with dysfunction of the noradrenergic α 2 ‐adrenoceptor system induced by impaired glucose metabolism. These insights targeting the noradrenergic‐metabolic axis might be a new strategy for sugar‐induced depression subtypes.
-
Journal of Neurochemistry, 169(11), Nov 20, 2025ABSTRACT Psychiatric disorders such as major depressive disorder are closely linked to the intestinal environment, suggesting intestinal health may contribute to their prevention. Prebiotics, which enhance intestinal health, are promising candidates for preventing psychiatric disorders. 1‐Kestose (kestose), a type of prebiotics, has shown potential, but its effects on psychiatric disorders remain unclear. In this study, we investigated whether kestose prevents abnormal behaviors induced by social isolation (SI) stress and which underlies mechanisms of preventive effects. C57BL/6J male mice (3 weeks old) were divided into two groups: individually housed (SI) group and housed five mice per cage (GH) group. Each group received either a normal diet or a kestose diet (5% kestose) for 5 weeks daily until the end of the behavioral testing. Kestose prevented the SI‐induced abnormal behaviors including reduced sociality, impaired spatial recognition, and heightened anxiety, which were associated with suppressed microglial activation in the hippocampus. Kestose altered the diversity of gut microbiota and increased the abundance of Bacteroides sartorii . Furthermore, short‐chain fatty acids (SCFAs) such as butyric acid, acetic acid, and propionic acid, produced by intestinal microbiota, were increased after kestose supplementation. Positive correlations were observed between B. sartorii abundance and SCFA levels, suggesting that B. sartorii contributes to SCFA production. Notably, both B. sartorii and SCFAs were strongly associated with the abnormal behaviors by SI. These findings suggest that kestose prevents SI‐induced abnormal behaviors by modulating gut microbiota, particularly B. sartorii , through an increase of SCFA production. Taken together, kestose could be used as a promising prebiotic intervention for psychiatric disorders. image
-
European Journal of Pharmacology, 178407-178407, Nov, 2025
-
Pharmacological Research, 221 107986-107986, Nov, 2025
Misc.
950-
Mol. Psychiat., 8 217-224, 2003 Peer-reviewed
-
Learn. Mem., 10 108-115, 2003 Peer-reviewed
-
Brain Res., 978 104-114, 2003 Peer-reviewed
-
Neuroscience, 119 399-419, 2003 Peer-reviewed
-
Effect of AD-5423 on animal model of schizophrenia: phencyclidine-induced behavioral changes in miceNeuroreport, 14 269-272, 2003 Peer-reviewed
-
FASEB J., 17 50-52, 2003 Peer-reviewed
-
22(6) 270-270, Dec 25, 2002
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology, 22(6), Dec 25, 2002
-
22(6) 341-341, Dec 25, 2002
-
Journal of toxicological sciences, 27 11-16, Dec 25, 2002ダイエット商品には根強い需要がある。中国の健康茶をイメージさせるダイエット食品に対して,日本の消費者は無防備である。個人輸入やインターネット販売によって,法の網をかいくぐり,危険な健康食品ややせ薬が,消費者の手元に簡単に届くことが,大きな社会問題となっている。中国製ダイエット食品による健康被害が報告された。これらのダイエット食品に含まれており,問題となっているのが食欲抑制剤「フェンフルラミン」である。これは,食欲抑制効果を期待して人為的に添加されたものと推察されている。フェンフルラミンは,中枢性セロトニン(5-HT)作動性食欲抑制薬であり,肥満症の治療に使用される。フェンフルラミンの5-HT神経系を介した精神神経学的副作用について,数多くの報告があり,不安を惹起し,認知機能,睡眠,人格などに影響を与えるのではないかと考えられている。フェンフルラミンの投与により,持続的な脳内5-HTレベルの低下を伴う,うつ状態が誘導される。原因として5-HT神経繊維の脱落および5-HT再取り込み部位の減少が報告されている。フェンフルラミンの濫用はまれであるが,薬物濫用歴のある者がフェンフルラミンを濫用したケースがあり,多幸症,知覚変化,非現実感のような症状が発現している。動物実験では依存性獲得は認められていない。フェンフルラミンの過量投与により,精神障害,振せん(震え),眠気,錯乱,紅潮,発熱...
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology, 22(6) 273-273, Dec 25, 2002
-
Folia pharmacologica Japonica, 120 24P-29P, Nov 10, 2002
-
日本医療薬学会年会講演要旨集, 12 194-194, Sep 24, 2002
-
日本医療薬学会年会講演要旨集, 12 265-265, Sep 24, 2002
-
Behav Brain Res, 133 135-141, Jul, 2002 Peer-reviewed
-
The annual proceedings of Gifu College of Pharmacy, 51 76-76, Jun 30, 2002
-
医学のあゆみ, 201(9) 703-707, Jun 1, 2002
-
Folia Pharmacologica Japonica, 119(6) 327-335, Jun 1, 2002The NMDA subtype of glutamate receptor (GluR) plays an important role in excitatory neurotransmission, synaptic plasticity, brain development, and neurodegeneration. NMDA receptors are inherent high Ca2+-permeable channels, which are formed by heteromeric assembly of the GluRζ1 subunit (NR1) and any one of four GluRε subunits (GluRε1-4; NR2A-D). Mice lacking the GluRε1 subunit exhibited a malfunction of NMDA receptors, as evidenced by reduction of NMDA receptor channel current, hippocampal long-term potentiation, [3H]MK-801 binding, and NMDA-stimulated 45Ca2+ uptake. A biochemical analysis revealed a hyperfunction of dopaminergic and serotonergic neuronal systems in the frontal cortex and striatum of GluRε1 mutant mice. The enhancement of dopaminergic neuronal activity in the striatum, at least, due to the disinhibition of inhibitory GABAergic neuronal input. GluRε1 mutant mice showed an increase of locomotor activity in a novel environment attributed to the hyperfunction of the dopaminergic neuronal system, and an impairment of spatial, contextual, and latent learning. These findings provide evidence that NMDA receptors regulate behavior through the modulation of not only glutamatergic but also GABAergic and dopaminergic neuronal systems. Moreover, it is suggested that GluRε1 mutant mice are useful as an animal model, which is associated with the malfunction of NMDA receptors and hyperfunction of the dopaminergic neuronal system.<br>
-
TDM研究, 19(2) 171-172, Apr, 200241歳男.生体肝移植3日前から28日後までシクロスポリン(CY)・マイクロエマルジョン(150〜750mg/日)を投与した.移植3日前のCYのAUC(0-2hr)/用量が9.73ng・hr/ml/mgであったのに対し,移植1日後は4.14,2日後は3.76,14日後は2.31ng・hr/ml/mgと減少した.以降は17日後5.91,21日後9.01ng・hr/ml/mgと回復した.総ビリルビン量,直接ビリルビン量も移植10日後までは上昇したが,それ以降減少した.AUC(0-2hr)/用量と総・直接ビリルビン量との間には負の相関を認めた.プロトロンビン時間及び活性化部分トロンボプラスチン時間は移植直後各々30.4秒,48.8秒と高値であったが,2日後より減少し始め,17日後では14.6秒,27.9秒となった
-
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 28(1) 16-21, Feb 10, 2002In hematopoietic cell transplantation, amphotericin B (AMPH) syrup is widely used for the prevention of local fungal infections in the intraoral and gastrointestinal tracts. However, the dosage compliance tends to be poor due to its unpleasant taste. We therefore developed a candy preparation for AMPH in order to improve compliance. In this study, we examined the thermostability, stability under storage and the dissolution pattern of AMPH in this preparation. The oral contents of AMPH after administration in the candy preparation were also measured in healthy volunteers. A low calorie sweetener was heated to melt and cooled down to several temperatures (150-190℃). After cooling, AMPH syrup or powder grinding, tablets were added (9 mg/ 3 g/piece: the final contents). The results of a thermostability examination show that AMPH was not affected at 150℃, however, it tended to be damaged at higher temperatures. When one piece of AMPH candy preparation was administered for 30 sec to healthy volunteers, the oral concentration of AMPH is higher than 100 μg/mL for 10 min, which is more than the minimal inhibitory concentration (MIC) for Candida albicans. Furthermore, the results of a texture test using healthy volunteers indicate that the taste, i.e., flavor, feel on the tongue, etc of the candy preparation made from syrup was superior to that made from powder. These results suggest that a sufficient oral concentration of AMPH to prevent fungal infection was obtained in this candy preparation. As a result, this candy preparation may improve not only the dosage compliance but also the QOL of the patients.
-
JOURNAL OF AFFECTIVE DISORDERS, 68(1) 127-127, Feb, 2002
-
Japanese Journal of Clinical Pharmacology and Therapeutics, 33(3) 85-91, 2002
-
JAPANESE JOURNAL OF PHARMACOLOGY, 88 93P-93P, 2002
-
JAPANESE JOURNAL OF PHARMACOLOGY, 88 241P-241P, 2002
-
JAPANESE JOURNAL OF PHARMACOLOGY, 88 27P-27P, 2002
-
JAPANESE JOURNAL OF PHARMACOLOGY, 88 197P-197P, 2002
-
JAPANESE JOURNAL OF PHARMACOLOGY, 88 28P-28P, 2002
-
Eur J Pharmacol., 453(1) 91-98, 2002
-
Neuropsychopharmacology, 26 259-268, 2002 Peer-reviewed
-
Free Radic. Biol. Med., 32 1324-1332, 2002 Peer-reviewed
-
Brain Res., 957 278-286, 2002 Peer-reviewed
-
Behav. Brain Res., 134 139-149, 2002 Peer-reviewed
-
Peptides, 23 1271-1283, 2002
-
Jpn. J. Neuropsychopharmacol., 21 125-132, 2002
-
Neuropharmacology, 42 764-771, 2002 Peer-reviewed
Books and Other Publications
14Presentations
13-
日本医療薬学会年会講演要旨集, Oct 25, 2010
Research Projects
40-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2023 - Mar, 2026
-
科学研究費助成事業 基盤研究(B), 日本学術振興会, Apr, 2023 - Mar, 2026
-
科学研究費助成事業 基盤研究(C), 日本学術振興会, Apr, 2020 - Mar, 2023
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2019 - Mar, 2022
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science, Apr, 2017 - Mar, 2022




